Investors bought shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on weakness during trading on Thursday. $59.77 million flowed into the stock on the tick-up and $51.16 million flowed out of the stock on the tick-down, for a money net flow of $8.61 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 29th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($2.23) for the day and closed at $135.43

Several research analysts have recently weighed in on ALXN shares. BMO Capital Markets started coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, April 6th. They set a “market perform” rating and a $165.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Alexion Pharmaceuticals from $195.00 to $210.00 in a research note on Friday, April 8th. Vetr upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $161.67 price objective on the stock in a research note on Monday, April 11th. Leerink Swann restated an “outperform” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 10th. Finally, Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 17th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $185.66.

The company has a market capitalization of $30.37 billion and a price-to-earnings ratio of 340.28. The company’s 50-day moving average is $124.55 and its 200 day moving average is $139.37.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The company had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. The business’s revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.44 EPS. On average, analysts expect that Alexion Pharmaceuticals Inc. will post $4.71 earnings per share for the current year.

In related news, EVP John B. Moriarty sold 918 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $135.72, for a total transaction of $124,590.96. Following the completion of the sale, the executive vice president now owns 51,360 shares in the company, valued at $6,970,579.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Martin Mackay sold 4,097 shares of the firm’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $139.20, for a total transaction of $570,302.40. Following the sale, the executive vice president now owns 42,706 shares of the company’s stock, valued at approximately $5,944,675.20. The disclosure for this sale can be found here.

Several institutional investors have bought and sold shares of the company. Robeco Institutional Asset Management B.V. increased its position in Alexion Pharmaceuticals by 18.9% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 9,909 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 1,574 shares during the last quarter. Pitcairn Co. increased its position in Alexion Pharmaceuticals by 20.9% in the fourth quarter. Pitcairn Co. now owns 16,382 shares of the biopharmaceutical company’s stock valued at $3,125,000 after buying an additional 2,835 shares during the last quarter. Cibc World Markets Corp increased its position in Alexion Pharmaceuticals by 21.2% in the fourth quarter. Cibc World Markets Corp now owns 18,974 shares of the biopharmaceutical company’s stock valued at $3,619,000 after buying an additional 3,324 shares during the last quarter. Ashburton Jersey Ltd acquired a new position in Alexion Pharmaceuticals during the fourth quarter valued at $3,655,000. Finally, Advantus Capital Management Inc increased its position in Alexion Pharmaceuticals by 2.7% in the fourth quarter. Advantus Capital Management Inc now owns 21,882 shares of the biopharmaceutical company’s stock valued at $4,174,000 after buying an additional 583 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.